中文
 

Follow us 

Hot Topic
Market News
Events & Promo
Career Tips
Education News
Health & Life
Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.
PRNewswire

Zhimeng Biopharma has completed the patients enrollment of its investigational drug, CB03-154, in the pivotal Phase 2/3 ALS clinical trial.

Publish date: 31 Oct 2026

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

SHANGHAI, Oct. 31, 2026 /PRNewswire/ -- Shanghai Zhimeng Biopharma, Inc. ( "Zhimeng Biopharma") announced today that its independently developed next-generation potassium channel opener, CB03-154, intended for the treatment of amyotrophic lateral sclerosis (ALS), has successfully completed patient enrollment in its pivotal Phase 2/3 clinical trial, in total enrolled 255 patients. This significant milestone marks the entry of the critical stage in the clinical development of CB03-154 for ALS in China, laying a solid foundation for the upcoming analysis of topline data and potential new drug application submissions.

This pivotal clinical trial has been conducted in China, with Professor Fan Dongsheng from the 3rd Affiliated Hospital of Peking University serving as the national leading principal investigator (Leading PI), and involving a total of 15 clinical research centers in Mainland China. The study aims to evaluate the efficacy and safety of CB03-154 in patients with ALS, with the primary efficacy endpoint being the change from baseline in the ALSFRS‑R score at Week 39. Previously, CB03-154 received approval from the China CDE in July 2025 to initiate Phase 2/3 clinical trials for ALS, and in October 2023 it was granted Orphan Drug Designation (ODD) by the U.S. FDA.

As a rare disease, ALS poses numerous unique challenges in drug development. Notably, based on the current clinical progress, if the Phase 2 topline results are positive in the third quarter of 2027, Zhimeng Biopharma plans to submit a marketing application to the China CDE for a conditional approval. This strategy is expected to enable ALS patients to gain access to innovative therapies sooner, reflecting the company's patient‑centered R&D philosophy in the rare‑disease space.

CB03-154 is a next-generation, selective potassium‑channel opener of the voltage‑gated KCNQ2/3, independently discovered and developed by Zhimeng Biopharma, and possesses potential best-in-class properties. By modulating neuronal excitability and restoring the balance between excitation and inhibition, this compound has demonstrated neuroprotective effects on motor neurons in preclinical studies. The completion of enrollment in this pivotal clinical trial marks the entry of a critical phase of validating the efficacy and safety of CB03-154 in patients with ALS.

In terms of clinical development, CB03-154 has been steadily advancing across multiple CNS indications. As of October 2026, in addition to the ALS indication, the drug has already entered the Phase 2 clinical trial for Focal Epilepsy in China and Australia. Furthermore, in June 2026, it received approval from the China CDE to initiate a Phase 2 trial for Major Depressive Disorder (MDD). The concurrent advancement of these three clinical studies fully underscores CB03-154's broad development potential in the field of central nervous system disorders.

Dr. Huanming Chen, the Founder and CEO of Zhimeng Biopharma, stated: "The completion of patient enrollment for the pivotal Phase 2/3 clinical trial of CB03-154 marks a strategically significant milestone for Zhimeng Biopharma in the field of ALS treatment. I would like to extend my sincere appreciation to Professor Fan Dongsheng and the investigators at all clinical research centers across China for their dedicated efforts, as well as to all ALS patients and their families who participated in the trial for their selfless commitment. Moving forward, we will spare no effort to advance clinical development and regulatory submissions, striving to bring a truly effective new treatment option to ALS patients in China and around the world as soon as possible."

About Zhimeng

Founded in 2018, Shanghai Zhimeng Biopharma, Inc, is a clinical stage biopharmaceutical company dedicated to the research and development of original small‑molecule drugs. The company focuses on liver diseases and central nervous system disorders, with a strong pipeline targeting treatment options for refractory epilepsy, neuropathic pain, amyotrophic lateral sclerosis (ALS), major depressive disorder (MDD), and other neurological conditions. In addition to its CNS portfolio, Zhimeng Biopharma has also made significant progress in the field of functional cure for chronic hepatitis B; its leading product, ZM‑H1505R (capsid inhibitor), has entered pivotal Phase 3 trial in China.

Disclaimer

This press release contains forward-looking statements. While Zhimeng considers the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by a number of hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.

For more information, please visit: www.corebiopharma.com

Follow us

Stay updated on the job market

Popular Articles

【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【首富發聲】本港出生率陷全球最低!去年新生兒急跌15.4%,馬斯克預言:若不改變將很快消失
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【打工仔減肥必睇】返工越耐越肥?盤點6個辦公室致肥壞習慣!踢走「過勞肥」全攻略
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【35歲後的頂級財富】港人公認人生贏家10大清單:你做到幾多個?
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【QS亞洲大學排名】港5大學強勢列入10強!港大蟬聯亞洲榜首,城大超中大首登全港第二
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」
【天氣轉涼】天文台:今晚急跌明早最低16度!新界溫差極大,打工仔出門必備「洋蔥式著法」

Hottest Tags

#馬斯克
#Elon Musk
#香港出生率
#少子化危機
#出生人口下跌
#生育津貼
#人口老化
#育兒成本
#打工仔減肥
#過勞肥
#辦公室致肥習慣
#寫字樓減肥

Viewed jobs
廢紙配料員 (Waste Paper Team Material Dosage Officer) 洲至有限公司
14 days ago
廢紙質檢管工 (Waster Paper Quality Production Supervisor) 洲至有限公司
14 days ago
製漿DCS技工 (Pulping DCS Machine Setter) 洲至有限公司
14 days ago
漿板操作工 (Pulp Board Team Operator) 洲至有限公司
14 days ago
理貨員【空缺編號 61-56435】
14 days ago
Viewed jobs
Contact Us
Notice
Back to Top
We use cookies to enhance your experience on our website. Please read and confirm your agreement to our Privacy Policy and Terms and Conditions before continue to browse our website. Read and Agreed